Strategies for finding new pharmacological targets for neuropathic pain.
Chronic pain of neuropathic origin is an unmet therapeutic challenge that may require the development of novel drug entities. The resources involved in developing novel drugs and testing them in clinical trials are so large that few candidates can be fully tested in practice. A poor choice can have major repercussions. At the same time, the research community has identified large numbers of potential pharmacological targets for analgesia in recent years, with individual investigators promoting favorites with increasing zeal. Because of the uncertain predictive value of animal models of neuropathic pain, it is essential to consider rational strategic approaches to selecting the most likely candidate targets.
Devor
Marshal
M
Institute of Life Sciences and Center for Research on Pain, Hebrew University of Jerusalem, Jerusalem 91904, Israel. marshlu@vms.huji.ac.il
D000700:Analgesics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003198:Computer Simulation; D004195:Disease Models, Animal; D006801:Humans; D008962:Models, Theoretical; D009437:Neuralgia / Q000188:drug therapy* / Q000503:physiopathology
D000700:Analgesics